http://www.acc.org/Feed?clinicalTopicID=07fcd7df-a463-421b-b927-d29a1be75766 Clinical Topic Feed: Anticoagulation Management and Atrial Fibrillation en /Latest-in-Cardiology/Articles/2026/03/25/21/27/sat-930am-championaf-acc-2026 Device-based left atrial appendage (LAA) closure was comparable to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in reducing the combined rate of death from cardiovascular causes, stroke, or systemic embolism at three years in patients with atrial fibrillation (AFib) who were candidates for anticoagulation, based on findings from the CHAMPION-AF trial presented at ACC.26 and simultaneously published in NEJM. In addition, LAA closure was superior to long-term NOAC therapy for pre-specified non–procedure-related bleeding over the same time period. 1774708380000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/04/14/11/eagles-eye-view-04mar2025 In this week’s View, Dr. Eagle looks at increased one-year mortality in younger patients undergoing transcatheter aortic valve replacement (TAVR). 1772636400000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/02/17/40/Key-Insights-From-the-ANDES-Trial The ANDES (Antithrombotic Therapy After Left Atrial Appendage Closure: Direct Oral Anticoagulants vs Dual Antiplatelet Therapy) trial results demonstrated that, in patients with nonvalvular atrial fibrillation who underwent left atrial appendage closure (LAAC), short-term direct oral anticoagulant (DOAC) therapy... 1772478060000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/01/01/Focus-on-EP In patients with atrial fibrillation (AFib), the most feared consequence is not the arrhythmia itself but the associated risk of stroke. Although decision-making tools to assess stroke risk in nonvalvular AFib have become more nuanced, the threshold to recommend oral anticoagulation (OAC) for stroke prevention has become lower over time. 1772370840000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/02/26/18/18/20-Year-Outcomes Twenty years after pulmonary vein isolation (PVI) during catheter ablation, stable sinus rhythm was maintained in a quarter of patients with symptomatic drug-refractory paroxysmal atrial fibrillation (PAF), including those taking antiarrhythmic drugs and those who had multiple ablation procedures, according to findings from a study published Feb. 17 in JACC: Clinical Electrophysiology. 1772131380000 Articles and Stories /Latest-in-Cardiology/Clinical-Trials/2026/03/03/18/35/OCEAN The OCEAN trial found that rivaroxaban did not result in a significantly lower incidence of stroke, systemic embolism or new covert embolic stroke compared with aspirin among patients at high risk for stroke who had undergone a catheter ablation for atrial fibrillation (AFib) at least one year prior. 1762627080000 Articles and Stories /Latest-in-Cardiology/Clinical-Trials/2026/03/03/18/35/CLOSURE-AF The CLOSURE-AF trial found that physician-directed standard medical therapy, which included anticoagulation medications when applicable, was better than left atrial appendage closure (LAAC) in patients with atrial fibrillation (AFib) and at high risk of stroke and major bleeding. 1762627080000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2025/10/21/18/47/Is-LAAO-More-Effective Left atrial appendage occlusion (LAAO) was associated with a lower rate of a composite of ischemic stroke, systemic embolism (SE), major bleeding or all-cause mortality when compared with oral anticoagulation (OAC) with apixaban and warfarin for treating patients with end-stage renal disease (ESRD) who also have atrial fibrillation (AFib), according to a study published Oct. 14 in JACC: Cardiovascular Interventions. 1761083760000 Articles and Stories /Latest-in-Cardiology/Articles/2025/08/26/11/47/fri-jacc-esc-2025 JACC Journals will be simultaneously publishing a plethora of science that will be presented during ESC Congress 2025 in Madrid, Spain. The following are a snapshot of the e-posters and oral abstracts: 1756457580000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2025/06/09/19/10/AZALEA-TIMI-71 In patients with atrial fibrillation (AFib) randomized to abelacimab vs. rivaroxaban, no statistically significant differences in bleeding risk were observed, suggesting that interruption of abelacimab treatment may not be necessary before invasive procedures with low bleeding risk... 1749497520000 Articles and Stories